{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:34:25Z","timestamp":1792802065891,"version":"4.5.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["CRC 1526"],"award-info":[{"award-number":["CRC 1526"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018877","name":"Stiftung Schleswig-Holsteinische Landesmuseen","doi-asserted-by":"publisher","award":["EXC 2167"],"award-info":[{"award-number":["EXC 2167"]}],"id":[{"id":"10.13039\/100018877","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Advances"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.omta.2026.201825","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T16:07:34Z","timestamp":1785427654000},"page":"201825","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["CD19\u00d7CD3 bispecific T cell engager treatment induces remission in experimental pemphigoid disease"],"prefix":"10.1016","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0773-3285","authenticated-orcid":false,"given":"Natalie","family":"Gross","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Jochimsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f6ren","family":"Dr\u00e4ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Theocharis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Recke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"van Beek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leon F.","family":"Schmidt-Jim\u00e9nez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Krohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Klausz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Bieber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf J.","family":"Ludwig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Peipp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omta.2026.201825_bib1","first-page":"1109","article-title":"Adjuvant treatment of severe\/refractory bullous pemphigoid with protein A immunoadsorption","volume":"16","author":"H\u00fcbner","year":"2018","journal-title":"JDDG J. Dtsch. Dermatol. Ges."},{"key":"10.1016\/j.omta.2026.201825_bib2","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1111\/jdv.18220","article-title":"Updated S2k guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV)","volume":"36","author":"Borradori","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.omta.2026.201825_bib3","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.3389\/fimmu.2019.01090","article-title":"High-Dose Intravenous Immunoglobulin in Skin Autoimmune Disease","volume":"10","author":"Hoffmann","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omta.2026.201825_bib4","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3389\/fimmu.2018.00248","article-title":"Effectiveness and safety of rituximab in recalcitrant pemphigoid diseases","volume":"9","author":"Lamberts","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omta.2026.201825_bib5","article-title":"Epidermolysis Bullosa Acquisita: The 2019 Update","volume":"5","author":"Koga","year":"2018","journal-title":"Front. Med."},{"key":"10.1016\/j.omta.2026.201825_bib6","doi-asserted-by":"crossref","first-page":"38357","DOI":"10.1038\/srep38357","article-title":"T cells mediate autoantibody- induced cutaneous inflammation and blistering in epidermolysis bullosa acquisita","volume":"6","author":"Bieber","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omta.2026.201825_bib7","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1016\/j.jid.2016.07.013","article-title":"Prevalence and Age Distribution of Pemphigus and Pemphigoid Diseases in Germany","volume":"136","author":"H\u00fcbner","year":"2016","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.omta.2026.201825_bib8","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1038\/jid.2012.35","article-title":"Incidence and mortality of bullous pemphigoid in France","volume":"132","author":"Joly","year":"2012","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.omta.2026.201825_bib9","first-page":"72","article-title":"Mortality in Patients with Bullous Pemphigoid: A Retrospective Cohort Study, Systematic Review and Meta-analysis","volume":"99","author":"Kridin","year":"2018","journal-title":"Acta Derm. Venerol."},{"key":"10.1016\/j.omta.2026.201825_bib10","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jaad.2019.03.049","article-title":"Rituximab therapy in patients with bullous pemphigoid: A retrospective study of 20 patients","volume":"81","author":"Polansky","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.omta.2026.201825_bib11","article-title":"Rituximab, Omalizumab, and Dupilumab Treatment Outcomes in Bullous Pemphigoid: A Systematic Review","volume":"13","author":"Cao","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omta.2026.201825_bib12","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s40257-018-0401-6","article-title":"Rituximab and Omalizumab for the Treatment of Bullous Pemphigoid: A Systematic Review of the Literature","volume":"20","author":"Kremer","year":"2019","journal-title":"Am. J. Clin. Dermatol."},{"key":"10.1016\/j.omta.2026.201825_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.875492","article-title":"Unmet Medical Needs in Chronic, Non-communicable Inflammatory Skin Diseases","volume":"9","author":"Ujiie","year":"2022","journal-title":"Front. Med."},{"key":"10.1016\/j.omta.2026.201825_bib14","doi-asserted-by":"crossref","first-page":"e535","DOI":"10.1111\/jdv.18700","article-title":"Mortality in eight autoimmune bullous diseases: A global large-scale retrospective cohort study","volume":"37","author":"Boch","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.omta.2026.201825_bib15","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1093\/bjd\/ljae219","article-title":"Risk of death, major adverse cardiac events and relapse in patients with bullous pemphigoid treated with systemic or topical corticosteroids","volume":"191","author":"Kridin","year":"2024","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.omta.2026.201825_bib16","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41571-020-0347-5","article-title":"T cell-engaging therapies\u2014BiTEs and beyond","volume":"17","author":"Goebeler","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.omta.2026.201825_bib17","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1126\/science.aaf6756","article-title":"Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease","volume":"353","author":"Ellebrecht","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.omta.2026.201825_bib18","doi-asserted-by":"crossref","first-page":"6317","DOI":"10.1172\/JCI138416","article-title":"Antigen-specific B cell depletion for precision therapy of mucosal pemphigus vulgaris","volume":"130","author":"Lee","year":"2020","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.omta.2026.201825_bib19","doi-asserted-by":"crossref","first-page":"B18","DOI":"10.1016\/j.jid.2022.05.971","article-title":"LB952 A phase 1 trial of DSG3-CAART cells in mucosal-dominant pemphigus vulgaris (mPV) patients: Preliminary data","volume":"142","author":"Chang","year":"2022","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.omta.2026.201825_bib20","doi-asserted-by":"crossref","first-page":"e397912","DOI":"10.1200\/EDBK_397912","article-title":"High Cost of Chimeric Antigen Receptor T-Cells: Challenges and Solutions","volume":"43","author":"Cliff","year":"2023","journal-title":"Am. Soc. Clin. Oncol. Educ. Book."},{"key":"10.1016\/j.omta.2026.201825_bib21","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1038\/s41375-025-02574-x","article-title":"Emerging T-cell lymphomas after CAR T-cell therapy","volume":"39","author":"Braun","year":"2025","journal-title":"Leukemia"},{"key":"10.1016\/j.omta.2026.201825_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114071","article-title":"Application of blinatumomab, a bispecific anti-CD3\/CD19 T-cell engager, in treating severe systemic sclerosis: A case study","volume":"204","author":"Subklewe","year":"2024","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.omta.2026.201825_bib23","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1056\/NEJMc2407150","article-title":"Teclistamab-Induced Remission in Refractory Systemic Lupus Erythematosus","volume":"391","author":"Alexander","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omta.2026.201825_bib24","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1038\/s41591-024-02964-1","article-title":"Bispecific T cell engager therapy for refractory rheumatoid arthritis","volume":"30","author":"Bucci","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.omta.2026.201825_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1335998","article-title":"Bi-specific autoantigen-T cell engagers as targeted immunotherapy for autoreactive B cell depletion in autoimmune diseases","volume":"15","author":"Perico","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omta.2026.201825_bib26","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1056\/NEJMc2408786","article-title":"BCMA-Targeted T-Cell\u2013Engager Therapy for Autoimmune Disease","volume":"391","author":"Hagen","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omta.2026.201825_bib27","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in Relapsed or Refractory Multiple Myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omta.2026.201825_bib28","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omta.2026.201825_bib29","doi-asserted-by":"crossref","first-page":"282","DOI":"10.3390\/cancers17020282","article-title":"Comprehensive Review of Early and Late Toxicities in CAR T-Cell Therapy and Bispecific Antibody Treatments for Hematologic Malignancies","volume":"17","author":"Bangolo","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.omta.2026.201825_bib30","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/1346-8138.17577","article-title":"Comorbid diseases in bullous pemphigoid: A population-based case\u2013control study","volume":"52","author":"Kim","year":"2025","journal-title":"J. Dermatol."},{"key":"10.1016\/j.omta.2026.201825_bib31","doi-asserted-by":"crossref","first-page":"e872","DOI":"10.1111\/jdv.20603","article-title":"Risk of oesophageal strictures in mucous membrane pemphigoid: Insights from a real-world cohort study","volume":"39","author":"Olbrich","year":"2025","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.omta.2026.201825_bib32","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1537428","article-title":"Pemphigoid disease model systems for clinical translation","volume":"16","author":"Tigges","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omta.2026.201825_bib33","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.4049\/jimmunol.1300310","article-title":"B cells, dendritic cells, and macrophages are required to induce an autoreactive CD4 helper T cell response in experimental epidermolysis bullosa acquisita","volume":"191","author":"Iwata","year":"2013","journal-title":"J. Immunol."},{"key":"10.1016\/j.omta.2026.201825_bib34","article-title":"Cutaneous kinase activity correlates with treatment outcomes following PI3K delta inhibition in mice with experimental pemphigoid diseases","volume":"13","author":"Ghorbanalipoor","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omta.2026.201825_bib35","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1111\/bph.14986","article-title":"Treatment with anti-neonatal Fc receptor (FcRn) antibody ameliorates experimental epidermolysis bullosa acquisita in mice","volume":"177","author":"Kasprick","year":"2020","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.omta.2026.201825_bib36","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/JID.2015.361","article-title":"Dimethylfumarate Impairs Neutrophil Functions","volume":"136","author":"M\u00fcller","year":"2016","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.omta.2026.201825_bib37","first-page":"3969","article-title":"Pharmacokinetics of monoclonal immunoglobulin G1, F(ab\u2019)2, and Fab\u2019 in mice","volume":"46","author":"Covell","year":"1986","journal-title":"Cancer Res."},{"key":"10.1016\/j.omta.2026.201825_bib38","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1097\/CJI.0b013e318186c8b4","article-title":"A Novel CD19-directed Recombinant Bispecific Antibody Derivative With Enhanced Immune Effector Functions for Human Leukemic Cells","volume":"31","author":"Kellner","year":"2008","journal-title":"J. Immunother."},{"key":"10.1016\/j.omta.2026.201825_bib39","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1177\/2040620716640422","article-title":"The role of blinatumomab in patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"7","author":"Benjamin","year":"2016","journal-title":"Ther. Adv. Hematol."},{"key":"10.1016\/j.omta.2026.201825_bib40","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-Cell Therapy in Autoimmune Disease\u2014A Case Series with Follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omta.2026.201825_bib41","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.clim.2007.10.004","article-title":"A novel subset of memory B cells is enriched in autoreactivity and correlates with adverse outcomes in SLE","volume":"126","author":"Nicholas","year":"2008","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.omta.2026.201825_bib42","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1376096","article-title":"Structural and functional characterization of IgG- and non-IgG-based T-cell-engaging bispecific antibodies","volume":"15","author":"Mohan","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omta.2026.201825_bib43","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1200\/JCO.24.01008","article-title":"Linvoseltamab for Treatment of Relapsed\/Refractory Multiple Myeloma","volume":"42","author":"Bumma","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omta.2026.201825_bib44","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2022.2085535","article-title":"Effect of molecular size on interstitial pharmacokinetics and tissue catabolism of antibodies","volume":"14","author":"Rafidi","year":"2022","journal-title":"mAbs"},{"key":"10.1016\/j.omta.2026.201825_bib45","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1136\/ard-2024-226142","article-title":"CD19-CAR T-cell therapy induces deep tissue depletion of B cells","volume":"84","author":"Tur","year":"2025","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.omta.2026.201825_bib46","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1182\/blood-2016-01-694356","article-title":"Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy","volume":"128","author":"Bhoj","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.omta.2026.201825_bib47","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1084\/jem.20031330","article-title":"BCMA is essential for the survival of long-lived bone marrow plasma cells","volume":"199","author":"O\u2019Connor","year":"2004","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.omta.2026.201825_bib48","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/B978-0-7020-6896-6.00007-7","article-title":"B-Cell Development and Differentiation","volume":"107\u2013118","author":"Schroeder","year":"2019","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.omta.2026.201825_bib49","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1038\/s41467-017-01901-w","article-title":"Plasma cell survival in the absence of B cell memory","volume":"8","author":"Hammarlund","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omta.2026.201825_bib50","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/nrrheum.2009.184","article-title":"CD19: a promising B cell target for rheumatoid arthritis","volume":"5","author":"Tedder","year":"2009","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.omta.2026.201825_bib51","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1038\/s41467-024-47801-8","article-title":"Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed\/refractory multiple myeloma: a phase I\/II trial","volume":"15","author":"Shi","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omta.2026.201825_bib52","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1073\/pnas.84.5.1374","article-title":"Identification of a monoclonal antibody specific for a murine T3 polypeptide","volume":"84","author":"Leo","year":"1987","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.omta.2026.201825_bib53","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1182\/blood-2008-03-144600","article-title":"Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells","volume":"112","author":"Peipp","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.omta.2026.201825_bib54","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.4049\/jimmunol.177.5.3461","article-title":"Induction of complement-fixing autoantibodies against type VII collagen results in subepidermal blistering in mice","volume":"177","author":"Sitaru","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.omta.2026.201825_bib55","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1111\/exd.13415","article-title":"In vitro and in vivo models to investigate the pathomechanisms and novel treatments for pemphigoid diseases","volume":"26","author":"Bieber","year":"2017","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.omta.2026.201825_bib56","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1002\/cpph.55","article-title":"Drug Discovery for Pemphigoid Diseases","volume":"84","author":"Kasprick","year":"2019","journal-title":"Curr. Protoc. Pharmacol."},{"key":"10.1016\/j.omta.2026.201825_bib57","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1343299","article-title":"Inhibition of interferon gamma impairs induction of experimental epidermolysis bullosa acquisita","volume":"15","author":"Gross","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omta.2026.201825_bib58","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.jdermsci.2017.05.016","article-title":"Increased TREM-1 expression in inflamed skin has no functional impact on the pathogenesis of cutaneous disorders","volume":"88","author":"Dr\u00e4ger","year":"2017","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.omta.2026.201825_bib59","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/j.jid.2021.08.448","article-title":"Multiple Modes of Action Mediate the Therapeutic Effect of Intravenous IgG in Experimental Epidermolysis Bullosa Acquisita","volume":"142","author":"Pipi","year":"2022","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.omta.2026.201825_bib60","doi-asserted-by":"crossref","first-page":"5043","DOI":"10.4049\/jimmunol.1100796","article-title":"Complement-Fixing Anti-Type VII Collagen Antibodies Are Induced in Th1-Polarized Lymph Nodes of Epidermolysis Bullosa Acquisita-Susceptible Mice","volume":"187","author":"Hammers","year":"2011","journal-title":"J. Immunol."}],"container-title":["Molecular Therapy Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3117387X26001606?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3117387X26001606?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T15:16:09Z","timestamp":1789053369000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S3117387X26001606"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":60,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S3117387X26001606"],"URL":"https:\/\/doi.org\/10.1016\/j.omta.2026.201825","relation":{},"ISSN":["3117-387X"],"issn-type":[{"value":"3117-387X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CD19\u00d7CD3 bispecific T cell engager treatment induces remission in experimental pemphigoid disease","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omta.2026.201825","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"201825"}}